Q3 EPS Estimate for Phio Pharmaceuticals Reduced by Analyst

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Stock analysts at Sidoti lowered their Q3 2026 EPS estimates for shares of Phio Pharmaceuticals in a report issued on Friday, August 7th. Sidoti analyst A. Hantman now expects that the company will post earnings of ($0.35) per share for the quarter, down from their prior estimate of ($0.31). The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.38) per share. Sidoti also issued estimates for Phio Pharmaceuticals’ Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.42) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.45) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, hitting the consensus estimate of ($0.36).

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Phio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $14.00.

Phio Pharmaceuticals Trading Up 1.9%

Shares of NASDAQ:PHIO opened at $1.06 on Tuesday. The stock has a market capitalization of $12.32 million, a P/E ratio of -0.82 and a beta of 0.82. The stock’s 50-day moving average price is $1.04 and its 200-day moving average price is $1.12. Phio Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $4.19.

Institutional Trading of Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC lifted its position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 92,638 shares of the company’s stock after purchasing an additional 34,732 shares during the period. Geode Capital Management LLC owned 0.86% of Phio Pharmaceuticals worth $97,000 as of its most recent SEC filing. 57.31% of the stock is currently owned by institutional investors and hedge funds.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.